Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination of acetylcysteine (NAC) and doxycycline. Acetylcysteine is a mucolytic agent that breaks disulfide links in mucoproteins to reduce viscosity, while also possessing antioxidant and anti-inflammatory properties. Doxycycline is a broad-spectrum tetracycline antibiotic that works by inhibiting bacterial protein synthesis. The combination may be used for respiratory infections where both bacterial infection and mucus accumulation are concerns, though research shows mixed effects with some studies indicating NAC can promote bacterial resistance to doxycycline in certain bacteria.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on acetylcysteine + doxycycline.